ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ADCT vs INO // FORWARD P/E MULTIPLE

ADC Therapeutics SA (NYSE) VS. Inovio Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ADCT 3 — INO 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ADCT VS. INO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ADCT INO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 92.90% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 14.90% -65.00% +79.90 ADCT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 5/9 2/9 +3.00 ADCT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.3 72.7 -18.40 INO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $196.6M $195.4M $1.2M ADCT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ADCT REV INO REV ADCT GROSS % INO GROSS % ADCT FCF INO FCF
FY 2025 $81.4M $65.3K 92.9% — -$141.4M -$88.9M
FY 2024 $70.8M $217.8K 91.6% — -$124.7M -$104.6M
FY 2023 $69.1M $832.0K — — -$118.7M -$124.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ADCT // BETA —
INO // BETA —